See the DrugPatentWatch profile for norditropin
What Norditropin Treats
Norditropin is a brand of somatropin, a recombinant human growth hormone used to treat growth hormone deficiency in children and adults. In children, it addresses short stature from conditions like Turner syndrome, Prader-Willi syndrome, chronic kidney disease, or idiopathic short stature. In adults, it replaces growth hormone lost due to pituitary disease, hypothalamic disease, surgery, radiation, or trauma.[1]
How Norditropin Works
It mimics the body's natural growth hormone, stimulating growth in bones and tissues, increasing muscle mass, and reducing body fat. Administered via daily subcutaneous injection using a prefilled pen for precise dosing.[1][2]
Common Uses by Patient Group
Children: Promotes linear growth in those with confirmed growth hormone deficiency or specific syndromes; also approved for Noonan syndrome and small for gestational age kids who fail to catch up by age 2-4.[1]
Adults: Manages growth hormone deficiency symptoms like reduced energy, muscle loss, and fat gain.[2]
Who Makes Norditropin and Delivery Options
Novo Nordisk manufactures it. Available in FlexPro pens (5mg/1.5mL, 10mg/1.5mL, 15mg/1.5mL, 30mg/3mL) for user-friendly injection without needles exposed.[1][2]
Key Side Effects Patients Report
Injection site reactions, headaches, joint/muscle pain, swelling, and elevated blood sugar. Rare risks include increased intracranial pressure or scoliosis progression in fast-growing kids. Long-term use requires monitoring for glucose intolerance or cancer risk in predisposed patients.[1][2]
When Is It Not Used?
Contraindicated in active cancer, critical illness, or breathing problems post-surgery. Not for idiopathic short stature without growth hormone testing.[1]
Patent Status and Availability
Novo Nordisk holds patents on Norditropin formulations; check DrugPatentWatch.com for expiry dates on specific strengths, as challenges could allow generics sooner.[3]
[1] https://www.norditropin.com
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020280s089lbl.pdf
[3] https://www.drugpatentwatch.com/p/tradename/NORDITROPIN